Analysis of the effect of therapy reductions on EFS according to the major prognostic factors
| . | First comparison . | P* . | Second comparison . | P* . | ||
|---|---|---|---|---|---|---|
| No. of patients full/half-dose CPM . | HR of event (90% CI) . | No. of patients M1/no M1 . | HR of event (90% CI) . | |||
| LDH level | ||||||
| 2N or less | 196/196 | 1.35 (0.63-2.9) | — | 192/200 | 1.49 (0.67-3.3) | — |
| Greater than 2N | 118/113 | 1.25 (0.70-2.2) | .87 | 120/111 | 0.82 (0.46-1.5) | .25 |
| Stage | ||||||
| I-II | 100/92 | 1.59 (0.34-7.3) | — | 93/99 | 3.78 (0.59-24) | — |
| III | 205/208 | 1.31 (0.79-2.2) | — | 213/200 | 1.03 (0.63-1.7) | — |
| IV | 16/16 | 0.88 (0.15-4.9) | .84 | 15/17 | 0.18 (0.02-1.9) | .31 |
| Burkitt | 228/222 | 1.72 (0.93-3.2) | — | 231/219 | 1.33 (0.73-2.4) | — |
| DLBC | 70/81 | 0.97 (0.45-2.1) | .32 | 69/82 | 0.82 (0.38-1.8) | .46 |
| Not PMLBL | 306/299 | 1.48 (0.89-2.5) | — | 304/301 | 1.07 (0.65-1.8) | — |
| PMLBL | 15/17 | 0.52 (0.13-2.1) | .20 | 17/15 | 0.72 (0.21-2.5) | .87 |
| . | First comparison . | P* . | Second comparison . | P* . | ||
|---|---|---|---|---|---|---|
| No. of patients full/half-dose CPM . | HR of event (90% CI) . | No. of patients M1/no M1 . | HR of event (90% CI) . | |||
| LDH level | ||||||
| 2N or less | 196/196 | 1.35 (0.63-2.9) | — | 192/200 | 1.49 (0.67-3.3) | — |
| Greater than 2N | 118/113 | 1.25 (0.70-2.2) | .87 | 120/111 | 0.82 (0.46-1.5) | .25 |
| Stage | ||||||
| I-II | 100/92 | 1.59 (0.34-7.3) | — | 93/99 | 3.78 (0.59-24) | — |
| III | 205/208 | 1.31 (0.79-2.2) | — | 213/200 | 1.03 (0.63-1.7) | — |
| IV | 16/16 | 0.88 (0.15-4.9) | .84 | 15/17 | 0.18 (0.02-1.9) | .31 |
| Burkitt | 228/222 | 1.72 (0.93-3.2) | — | 231/219 | 1.33 (0.73-2.4) | — |
| DLBC | 70/81 | 0.97 (0.45-2.1) | .32 | 69/82 | 0.82 (0.38-1.8) | .46 |
| Not PMLBL | 306/299 | 1.48 (0.89-2.5) | — | 304/301 | 1.07 (0.65-1.8) | — |
| PMLBL | 15/17 | 0.52 (0.13-2.1) | .20 | 17/15 | 0.72 (0.21-2.5) | .87 |
Interaction test
CPM indicates cyclophosphamide, COPADM and M1; see Figure 1; PMLBL, primary mediastinal large B-cell lymphoma. — indicates not applicable.